Synthesis and characterization of a macromolecular magnetic resonance imaging and delivery system with hyaluronic acid as a carrier

Biochem Biophys Res Commun. 2023 Jan 8:639:183-188. doi: 10.1016/j.bbrc.2022.11.087. Epub 2022 Nov 29.

Abstract

Using hyaluronic acid (HA) as macromolecular drug carriers, a glutathione-responsive imaging drug delivery system HA-SS-a-Gd-DOTA was formed by conjugating gadolinium chelates and cytarabine. This system exhibited T1-reflexivity (21.9 mmol-1 L s-1, 0.5 T) that was higher than that of gadoterate meglumine. In an acidic environment, in vitro drug release reached 63.4% in 24 h. Low cytotoxicity indicated that this system has good biocompatibility. In vivo mouse imaging studies showed that tumor signaling was significantly enhanced. About 58% of the signal enhancement was obtained 50 min after injection of the drug. The degradation of the hyaluronic acid macromolecular chains in vivo makes it an ideal tumor imaging diagnostic agent because it did not cause damage to important organs of the mice.

Keywords: Contrast agent; Hyaluronic acid; MRI; Tumor targets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Contrast Media
  • Hyaluronic Acid
  • Macromolecular Substances
  • Magnetic Resonance Imaging / methods
  • Mice
  • Neoplasms*
  • Organometallic Compounds*

Substances

  • Hyaluronic Acid
  • Contrast Media
  • Macromolecular Substances
  • Organometallic Compounds